CSA Medical Series B preferred stock
$20,500,000
About CSA Medical:
CSA Medical develops and manufactures a proprietary interventional spray cryotherapy technology platform utilizing unique properties of liquid nitrogen spray delivered by a software-driven device with specialty catheters that enable the delivery of spray cryogen inside the body to flash freeze and destroy unwanted tissue allowing for a rejuvenative pattern of healing. The RejuvenAir System is now approved in the EU and under clinical investigation in the United States.